References
- Hanquet G, Valenciano M, Simondon F, Moren A. Vaccine effects and impact of vaccination programmes in post-licensure studies. Vaccine 2013;31:5634-42
- Benefit-Risk balance for marketed drugs: evaluating safety signals. Report of CIOMS Working Group IV, 1998. Available from: www.cioms.ch/publications/g4-benefit-risk.pdf [Last accessed 9 May 2014]
- Guideline on good pharmacovigilance practices (GVP). EMA/838713/2011 European Medicines Agency, 2012. Available from: www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129134.pdf [Last accessed 25 January 2014]
- Delegated act on post-authorisation efficacy studies. Article 10B of Regulation (EC) No 726/2004 and Article 22B of Directive 2001/83/EC). European Commission, Health Consumers Directorate-General. 2012. Available from: http://ec.europa.eu/health/files/pharmacovigilance/2012_11_28_pc_paes.pdf [Last accessed 22 October 2013]
- Wong CA, Saraiya M, Hariri S, et al. Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries. Vaccine 2011;29:878-85
- Chang Y, Brewer NT, Rinas AC, et al. Evaluating the impact of human papillomavirus vaccines. Vaccine 2009;27:4355-62
- Howell-Jones R, Soldan K, Wetten S, et al. Declining genital warts in young women in England associated with HPV 16/18 vaccination: an ecological study. J Infect Dis 2013;208:1397-403
- Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301-14
- Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:89-99
- Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012;30(Suppl 5):F123-38
- Wheeler CM, Castellsagué X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:100-10
- Macartney KK, Chiu C, Georgousakis M, Brotherton JM. Safety of human papillomavirus vaccines: a review. Drug Saf 2013;36:393-412
- Descamps D, Hardt K, Spiessens B, et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 2009;5:332-40
- Angelo M-G, Zima J, Tavares Da Silva F, et al. Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience. Pharmacoepidemiol Drug Saf 2014;23:456-65
- Angelo M-G, David M-P, Zima J, et al. Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol Drug Saf 2014;23:466-79
- Gasparini R, Bonanni P, Levi M, et al. Safety and tolerability of bivalent HPV vaccine: an Italian post-licensure study. Hum Vaccin 2011;7(Suppl):136-46
- MHRA Public assessment report Cervarix (HPV vaccine): update on UK safety covering the first two years of the HPV immunisation programme. Medicines and Healthcare products Regulatory Agency (MHRA), October 2010. Available from: www.mhra.gov.uk/PrintPreview/DefaultSplashPP/CON023340?ResultCount=10&DynamicListQuery=&DynamicListSortBy=xCreationDate&DynamicListSortOrder=Desc&DynamicListTitle=&PageNumber=1&Title=Human%20papillomavirus%20(HPV)%20vaccine [Last accessed 7 September 2012]
- Van’t Klooster T, Kemmeren J, Vermeer-de-Bondt P, et al. Adverse events following vaccination against human papillomavirus: Results of the 2010 campaign in the Netherlands. RIVM, 2011. Available from: www.rivm.nl/en/Library/Scientific/Reports/2011/december/Adverse_events_following_vaccination_against_human_papillomavirus_Results_of_the_2010_campaign_in_the_Netherlands?sp=cml2bXE9ZmFsc2U7c2VhcmNoYmFzZT01OTAzMDtyaXZtcT1mYWxzZTs=&pagenr=5904 [Last accessed 7 September 2014]
- The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. European Centre for Disease Prevention and Control (ECDC) Health Communication Unit. Eurosurveillance, 2010. Available from: www.eurosurveillance.org/viewarticle.aspx?ArticleId=19730 [Last accessed 10 September 2012]
- De Sanjosé S, Palefsky J. Cervical and anal HPV infections in HIV positive women and men. Virus Res 2002;89:201-11
- Adjorlolo-Johnson G, Unger ER, Boni-Ouattara E, et al. Assessing the relationship between HIV infection and cervical cancer in Côte d’Ivoire: a case-control study. BMC Infect Dis 2010;10:242
- Denny L, Hendricks B, Gordon C, et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Vaccine 2013;31:5745-53
- Evaluation of safety and immunogenicity of a human papillomavirus (HPV) vaccine in human immunodeficiency virus (HIV) infected females. Available from: http://clinicaltrials.gov/show/NCT01031069
- General recommendations on immunization–recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60:1-64
- Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009;5:705-19
- Pedersen C, Breindahl M, Aggarwal N, et al. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls. J Adolesc Health 2012;50:38-46
- Garcia-Sicilia J, Schwarz TF, Carmona A, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women. J Adolesc Health 2010;46:142-51
- Wheeler CM, Harvey BM, Pichichero ME, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial. Pediatr Infect Dis J 2011;30:e225-34
- Schmeink CE, Bekkers RLM, Josefsson A, et al. Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls. Vaccine 2011;29:9276-83
- Palmroth J, Merikukka M, Paavonen J, et al. Occurrence of vaccine and non-vaccine HPV types in adolescent Finnish females four years post vaccination. Int J Cancer 2012;131:2832-8
- Lehtinen M, French K, Dillner J, et al. Sound implementation of human papillomavirus vaccination as a community-randomized trial. Therapy 2008;5:289-94
- Effectiveness, safety and immunogenicity of GSK biologicals’ HPV vaccine GSK580299 (Cervarix TM) administered in healthy adolescents. Available from: http://clinicaltrials.gov/show/NCT00534638
- David M-P, Van Herck K, Hardt K, et al. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol 2009;115:S1-6
- Moscicki A-B, Wheeler CM, Romanowski B, et al. Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women. Vaccine 2012;31:234-41
- GSK Cervarix® two-dose schedule receives European marketing authorisation. GSK Media, 2013. Available from: http://www.gsk.com/media/press-releases/2013/gsk-cervarix–two-dose-schedule-receives-european-marketing-auth.html [Last accessed 8 February 2014]
- Aregay M, Shkedy Z, Molenberghs G, et al. Model-based estimates of long-term persistence of induced HPV antibodies: a flexible subject-specific approach. J Biopharm Stat 2013;23:1228-48
- Lehtinen M, Apter D, Dubin G, et al. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS 2006;17:517-21
- Lehtinen M, Idänpään-Heikkilä I, Lunnas T, et al. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy. Int J STD AIDS 2006;17:237-46
- Lehtinen M, Paavonen J. Effectiveness of preventive human papillomavirus vaccination. Int J STD AIDS 2003;14:787-92
- Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65
- Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55
- Romanowski B, de Borba PC, Naud PS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009;374:1975-85
- Naud PS, Roteli-Martins CM, De Carvalho NS, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: Final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccines Immunother 2014;10
- Mesher D, Howell-Jones R, Panwar K, et al. Reduction in HPV infection in young women following introduction of HPV immunisation in England. Vaccine 2013;32:26-32
- Kavanagh K, Pollock KGJ, Potts A, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer 2014;110:2804-11
- Pollock K, Potts A, Love J, et al. Early effect of the HPV bivalent vaccine on high-risk HPV prevalence and high-grade cervical abnormalities in Scotland. EUROGIN; Florence, Italy: 2013
- Fewer municipalities with low vaccination coverage. RIVM, 2013. Available from: www.rivm.nl/en/Documents_and_publications/Common_and_Present/Newsmessages/2013/Fewer_municipalities_with_low_vaccination_coverage [Last accessed 8 May 2014]
- Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007;6:723-39
- Garçon N, Segal L, Tavares F, Van Mechelen M. The safety evaluation of adjuvants during vaccine development: the AS04 experience. Vaccine 2011;29:4453-9
- Didierlaurent AM, Morel S, Lockman L, et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol Baltim Med 1950;183:6186-97
- Tavares Da Silva F, De Keyser F, Lambert P-H, et al. Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines. Vaccine 2013;31:1870-6
- Verstraeten T, Descamps D, David M-P, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008;26:6630-8
- Study assessing risk of autoimmune diseases in females (9–25 Years) exposed to Cervarix® in United Kingdom. Available from: http://clinicaltrials.gov/show/NCT01953822
- Wacholder S, Chen BE, Wilcox A, et al. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ 2010;340:c712
- Post-marketing safety study to assess the risk of spontaneous abortions in women exposed to Cervarix residing in UK. Available from: http://clinicaltrials.gov/show/NCT01905462